Background {#Sec1}
==========

Autoimmune diseases are multifactorial in origin. Genetic background confers susceptibility to disease onset but is not sufficient for disease development. Epigenetic mechanisms such as DNA methylation and histone modifications regulate gene expression levels and provide an alternative mechanism for modulating gene function and genetic changes. Importantly, DNA methylation plays an important role in T cell differentiation \[[@CR1], [@CR2]\], and the potential role of epigenetics in environment and genetics interaction has been widely suggested in autoimmunity \[[@CR3], [@CR4]\]. With these data in mind, we note that primary biliary cirrhosis (PBC) is characterized by the presence of high titers of circulating antimitochondrial antibodies (AMAs), innate immune system activation \[[@CR5]--[@CR7]\], and liver-infiltrating autoreactive CD4 and CD8 T lymphocytes \[[@CR8]--[@CR10]\], leading to the progressive destruction of small intrahepatic bile ducts \[[@CR11], [@CR12]\]. Genetic polymorphisms account for individual susceptibility to PBC in a minority of cases, as supported by genome-wide association (GWAS) data \[[@CR13]--[@CR17]\], while environmental factors may act through epigenetic changes, as demonstrated for specific genes \[[@CR18]--[@CR20]\]. It has long been known that there is a striking female sex bias in PBC \[[@CR21]\], and recent data has suggested involvement of sex chromosomes \[[@CR22], [@CR23]\]. For example, an enhanced X monosomy rate in peripheral lymphocytes has been demonstrated in women with PBC \[[@CR24]\], despite random X chromosome inactivation \[[@CR25]\], as well as an increased Y loss in men with PBC \[[@CR26]\].

We thus hypothesized that there is an X chromosome epigenetic component in PBC. Herein we performed an extensive X chromosome methylation analysis in CD4, CD8, and CD14 cells from PBC patients and controls, coupled with gene expression profile from the same cells. The frequency of CXCR3-expressing cells in peripheral blood is known to be higher in PBC patients, and CXCR3-positive cells are found in the portal areas of diseased livers, primarily on CD4+ T cells \[[@CR27]\]. Moreover, we report that the CXCR3 promoter is demethylated in CD4+ T cells from PBC patients and the expression level of CXCR3 in CD4+ T cells is significantly increased in comparison to controls and inversely correlated with the overall methylation levels of the CXCR3 promoter, indicating that promoter demethylation status contributed to CXCR3 overexpression in CD4+ T cells. Hence, we submit that there is an epigenetic mechanism that underlies CXCR3 expression in PBC. Our findings not only identify potentially relevant DNA methylation markers for the clinical characterization of PBC patients but also support the thesis that epigenetic changes may be critical for the clinical manifestations of PBC.

Results {#Sec2}
=======

DNA methylation {#Sec3}
---------------

Initially, X chromosome methylated DNA immunoprecipitation (MeDIP) arrays were performed on cell subsets from 10 PBC patients and 10 controls (Fig. [1](#Fig1){ref-type="fig"}). We identified 8 hypomethylated genes and 12 hypermethylated genes in CD4+ cells, 3 hypomethylated genes and 12 hypermethylated genes in CD8+ cells, and 9 hypomethylated genes and 10 hypermethylated genes in CD14+ cells in PBC compared with normal controls (Fig. [2](#Fig2){ref-type="fig"}, Table [1](#Tab1){ref-type="table"}). Gene ontology (GO) analysis was conducted to identify the cell component, molecular function, and biological processes of these genes. Bisulfite sequencing was thence used to validate the results of the MeDIP-ChIP. Based on the GO analysis, four genes were chosen for validation in CD4+, CD8+, and CD14+ cells from 20 additional PBC patients and 20 additional normal controls. Importantly, CXCR3 was demonstrated to be significantly hypomethylated in CD4+ T cells from PBC patients (Fig. [3](#Fig3){ref-type="fig"}), whereas UBE2A and FUNDC2 were hypermethylated in CD4+ T cells and CD8+ T cells, respectively, in PBC patients (Figs. [4](#Fig4){ref-type="fig"} and [5](#Fig5){ref-type="fig"}). IL1RAPL2 was hypermethylated in CD14+ cells in PBC (Fig. [6](#Fig6){ref-type="fig"}).Fig. 1Flow chart illustrating the study designFig. 2Differential methylation between PBC-affected subjects (*n* = 10) and healthy controls (*n* = 10) in CD4+, CD8+, and CD14+ cells represented in a heat map. The genomic locations of genes are shown on the *left* of the X chromosome ideogram. On the *right*, different methylated regions (DMR) of genes are identified in at least 6/10 samples in one group and 3/10 samples in the other. The predicted DMR along with the names of the genes in each cell examined is depicted as a two-dimensional heat map, respectively. *Black blocks* represent zero peaks, and *yellow blocks* symbolize different peak numbers corresponding to the *scale bar* at the bottomTable 1Differentially methylated genes between PBC patients (n = 10) and controls (n = 10) in CD4+ T cells, CD8+ T cells, and CD14+ cells from MeDIP arrayGene symbolPromoter methylationChromosome locationPeak startPeak endMolecular functionCD4+ T cells SHROOM2HypoXp22.397120729712217Protein binding; actin binding; ion channel activity ATP6AP2HypoXp11.44032509140325230Receptor activity; protein binding; peptidase activity CXCR3HypoXq137075490870755379Protein binding; receptor activity KIAA1210HypoXq24118168783118168934-- RAP2CHypoXq25131181458131182027Nucleotide binding; hydrolase activity HTATSF1HypoXq26.3135407214135407962RNA binding; nucleotide binding SRPK3HypoXq28152699372152700237Protein binding; nucleotide binding; protein kinase activity IDH3GHypoXq28152712248152713105Nucleotide binding; catalytic activity; binding SH3KBP1HyperXp22.1-p21.31981504819815499Kinase activity; protein binding PHEXHyperXp22.2-p22.12196076521961408Binding; peptidase activity USP9XHyperXp11.44082971640830189-- EBPHyperXp11.23-p11.224826528348265716-- PQBP1HyperXp11.234863869848639426DNA binding; protein binding; transcription regulator activity KDM5CHyperXp11.22-p11.215327082653271657Catalytic activity; binding; DNA binding; transferase activity IL13RA1HyperXq24117745388117746245Protein binding; receptor activity UBE2AHyperXq24118592639118593104Catalytic activity; protein binding; nucleotide binding CUL4BHyperXq23119578240119579025Protein binding DCAF12L1HyperXq25125513992125514963-- GPC4HyperXq26.1132376771132377010Protein binding FAM50AHyperXq28153325585153326034--CD8+ T cells MAGEB2HypoXp21.33014277530143514-- PIN4HypoXq137131869971318834DNA binding; catalytic activity IDH3GHypoXq28152713172152713419Nucleotide binding; catalytic activity; binding GPR143HyperXp22.396934699693810Binding; protein binding CHST7HyperXp11.234631779046318126Transferase activity NDUFB11HyperXp11.234688959646889747-- RBM10HyperXp11.234688959646889747RNA binding; nucleotide binding ZXDBHyperXp11.215763548957636052Nucleic acid binding; binding; protein binding; sequence-specific DNA binding transcription factor activity DOCK11HyperXq24117514077117514418Enzyme regulator activity; lipid binding; protein binding IL13RA1HyperXq24117745582117746125Protein binding; receptor activity RNF113AHyperXq24118889675118890227Binding; protein binding AIFM1HyperXq26.1129101688129102158Catalytic activity; nucleotide binding; protein binding; electron carrier activity; DNA binding MPP1HyperXq28153686370153686806Kinase activity; protein binding FUNDC2HyperXq28153908428153908659-- RAB39BHyperXq28154146437154146790Nucleotide bindingCD14+ cells SYAP1HypoXp22.21664793816648203-- DYNLT3HypoXp213759122737591696-- CASKHypoXp11.44166712641667877Protein binding; ATP binding; protein kinase activity GPR173HypoXp115309532353095568G protein-coupled receptor activity CITED1HypoXq13.17144196571442118Sequence-specific DNA binding transcription factor activity; protein binding; DNA binding; transcription regulator activity; chromatin binding; hydrolase activity GPRASP1HypoXq22.1101790525101790970Protein binding RNF128HypoXq22.3105824083105824257Binding; catalytic activity NSDHLHypoXq28151750127151750280Catalytic activity SSR4HypoXq28152710848152711207Calcium ion binding KAL1HyperXp22.3286592788659655Enzyme regulator activity; protein binding; carbohydrate binding; structural molecule activity SH3KBP1HyperXp22.1-p21.31981514819815397Protein binding USP11HyperXp11.234697694446977091Peptidase activity; protein binding; hydrolase activity PIM2HyperXp11.234866120748661380Protein kinase activity; nucleotide binding PCDH11XHyperXq21.39092137490921541Calcium ion binding IL1RAPL2HyperXq22103696629103696884Protein binding; receptor activity PSMD10HyperXq22.3107221347107221874Protein binding ATG4AHyperXq22.1-q22.3107221347107221874Peptidase activity DCAF12L1HyperXq25125513614125513941Protein binding FUNDC2HyperXq28153908232153908879--Fig. 3Bisulfite sequencing-based DNA methylation analysis of the CXCR3 promoter region in CD4+ T cells. **a** Chromosomal sequence location of the CXCR3 promoter that was analyzed by bisulfite sequencing. This region contains four CpG sites (*vertical bars*) within a 471 bp region overlapping the transcription start site as shown. **b** Representative bisulfite sequencing data from CD4+ cells of a PBC sample and a normal control, respectively. Each *circle* represents a CpG site, and each *line* represents an individually sequenced clone. *Filled circles* represent methylated sites (protected from bisulfite conversion), while *unfilled circles* represent unmethylated CpG sites (converted). **c** Mean methylation level was calculated for each individual CpG site within the CXCR3 promoter region for all clones for PBC (*n* = 20) versus healthy (*n* = 20) CD4+ cells. **d** Overall percentage of methylation of CXCR3 was determined by the total number of methylated sites out of the total CpG sites in all clones and graphed as mean ± SD for PBC (*n* = 20) versus healthy (*n* = 20) CD4+ cells. \*\**p* \< 0.01Fig. 4**a** Chromosomal sequence location of the region of the UBE2A promoter that was analyzed by bisulfite sequencing. This region contains 20 CpG sites (*vertical bars*) within a 542 bp region upstream of the transcription start site as shown. **b** Representative bisulfite sequencing data from CD4+ cells of a PBC sample and a normal control, respectively. Each *circle* represents a CpG site, and each *line* represents an individually sequenced clone. *Filled circles* represent methylated sites (protected from bisulfite conversion), while *unfilled circles* represent unmethylated CpG sites (converted). **c** Mean methylation level was calculated for each individual CpG site within the UBE2A promoter region for all clones for PBC (*n* = 20) versus healthy (*n* = 20) CD4+ cells. **d** Overall percentage of methylation of UBE2A was determined by the total number of methylated sites out of the total CpG sites in all clones and graphed as mean ± SD for PBC (*n* = 20) versus healthy (*n* = 20) CD4+ cells. \**p* \< 0.05Fig. 5**a** Chromosomal sequence location of the region of the FUNDC2 promoter that was analyzed by bisulfite sequencing. This region contains 80 CpG sites (*vertical bars*) within a 696 bp region close to the transcription start site as shown. **b** Representative bisulfite sequencing data from CD8+ cells of a PBC sample and a normal control, respectively. Each *circle* represents a CpG site, and each *line* represents an individually sequenced clone. *Filled circles* represent methylated sites (protected from bisulfite conversion), while *unfilled circles* represent unmethylated CpG sites (converted). **c** Mean methylation level was calculated for each individual CpG site within the FUNDC2 promoter region for all clones for PBC (*n* = 20) versus healthy (*n* = 20) CD8+ cells. **d** Overall percentage of methylation of FUNDC2 was determined by the total number of methylated sites out of the total CpG sites in all clones and graphed as mean ± SD for PBC (*n* = 20) versus healthy (*n* = 20) CD8+ cells. \**p* \< 0.05Fig. 6**a** Chromosomal sequence location of the region of the IL1RAPL2 promoter that was analyzed by bisulfite sequencing. This region contains 23 CpG sites (*vertical bars*) within a 423 bp region upstream of the transcription start site as shown. **b** Representative bisulfite sequencing data from CD14+ cells of a PBC sample and a normal control, respectively. Each *circle* represents a CpG site, and each *line* represents an individually sequenced clone. *Filled circles* represent methylated sites (protected from bisulfite conversion), while *unfilled circles* represent unmethylated CpG sites (converted). **c** Mean methylation level was calculated for each individual CpG site within the IL1RAPL2 promoter region for all clones for PBC (*n* = 20) versus healthy (*n* = 20) CD14+ cells. **d** Overall percentage of methylation of IL1RAPL2 was determined by the total number of methylated sites out of the total CpG sites in all clones and graphed as mean ± SD for PBC (*n* = 20) versus healthy (*n* = 20) CD14+ cells. \*\**p* \< 0.01

Gene expression {#Sec4}
---------------

CXCR3, UBE2A, FUNDC2, and IL1RAPL2 expression was studied by reverse transcription and quantitative polymerase chain reaction (RT-qPCR) in CD4+, CD8+, and CD14+ cells in a cohort of 30 PBC and 30 normal controls (Fig. [7](#Fig7){ref-type="fig"}).Fig. 7CXCR3 (**a**), and FUNDC2 (**b**) expression level was determined in CD4+, CD8+ T cells, and CD14+ cells in PBC patients and controls. Real-time threshold cycle values for cDNA were normalized with GADPH and compared to a calibrator. Limits (95 % CI) of the best-fit line are shown

Importantly, CXCR3 was significantly overexpressed in CD4+ T cells in PBC (*p* = 0.0055), whereas FUNDC2 was significantly less expressed in CD8+ T cells from PBC than controls (*p* = 0.0134). These results are concordant with the methylation data. IL1RAPL2 was not expressed in any cell subset in PBC or controls, and no significant differences were identified for UBE2A in the three subsets investigated (data not shown). Finally, a significant negative correlation between CXCR3 expression and overall methylation levels in CD4+ T cells was found in early-stage PBC patients (*p* \< 0.05) (Fig. [8a](#Fig8){ref-type="fig"}). Of note, there was no difference observed based on UDCA treatment (data not shown). In addition, our data demonstrated that CXCR3 expression levels in CD4+ T cells were significantly associated with duration of disease (*p* \< 0.01) (Fig. [8b](#Fig8){ref-type="fig"}) but not associated with age (data not shown).Fig. 8Correlation analysis was performed to evaluate the relationship between CXCR3 gene expression levels, methylation status of CXCR3 promoter, and disease duration. **a** CXCR3 expression in CD4+ T cells inversely correlates with methylation status of CXCR3 promoter. **b** CXCR3 expression in CD4+ T cells correlates with disease duration. Real-time threshold cycle values for CXCR3 cDNA were normalized with GADPH and compared to a calibrator. Calibrated CXCR3 expression levels were correlated to disease duration (months). 95 % confidence limits of the best-fit line are shown (*solid line*)

CD4 T cell phenotype {#Sec5}
--------------------

Finally, we quantified CD4 T cell populations expressing CXCR3 in both PBC (*n* = 20) and controls (*n* = 10) by flow cytometry. Based on the expression data, patients with PBC had an increased number in the periphery of CD4 T cells expressing CXCR3. In addition, both naïve and memory CD4 T cells from PBC expressed a higher frequency of CXCR3 cells in the periphery than controls. However, only activated CD4+CD45RO+ cells expressed significantly higher levels of CXCR3 (41.82 % ± 4.37 versus 27.57 % ± 2.61, *p* = 0.0094) (Fig. [9](#Fig9){ref-type="fig"}). Please note we included both early (*n* = 10) and advanced (*n* = 10) stage patients with PBC (data not shown).Fig. 9CD4 T cell populations expressing CXCR3 in PBC (*n* = 20) and controls (*n* = 10) were quantified by flow cytometry. In PBC, there is an increased number of CD4 T cells in the periphery expressing CXCR3, in both naïve (CD45RA) and memory cells (CD45RO). Activated CD4+CD45RO+ cells express significantly higher levels of CXCR3 in PBC (41.82 % ± 4.37) compared to controls (27.57 % ± 2.61) (*p* = 0.0094)

Discussion {#Sec6}
==========

As the case for most autoimmune diseases, PBC results from the contribution of genetic and environmental factors, reflected by incomplete concordance in monozygotic twins \[[@CR28]\]. Moreover, our group has suggested a significant role for X chromosome defects in PBC, based on the observation that women with PBC have a significantly enhanced monosomy X frequency in peripheral white blood cells compared to age- and disease stage-matched women with chronic viral hepatitis and to age-matched healthy women \[[@CR24]\]. Epigenetic mechanisms act at the interface of genetic and environmental influences on human phenotype and disease risk by altering gene expression levels without altering DNA sequence or chromosome structure. In the case of autoimmune diseases, epigenetic mechanisms have been implicated in the pathogenesis of systemic lupus erythematosus \[[@CR29], [@CR30]\] and type I diabetes \[[@CR31]\]. Moreover, we had previously explored the X chromosome epigenetic component in PBC \[[@CR18]\].

Importantly, PBC is a complex autoimmune disease involving autoreactive CD4+ and CD8+ T cell responses, present in human circulating lymphocytes and liver, B cell compartment, and innate immunity, including macrophages \[[@CR6], [@CR32]--[@CR34]\].

In this study, we investigated for the first time the DNA methylation status of the X chromosome in CD4+, CD8+, and CD14+ cells isolated from PBC patients and well-matched controls. We herein demonstrate that the CXCR3 promoter is demethylated in CD4+ T cells from PBC patients compared to controls, which is supported by a significantly higher expression of CXCR3 in the same cell subtype of PBC patients. CXCR3 gene encodes a G protein-coupled receptor with selectivity for three chemokines: CXCL9 or MIG (monokine induced by IFNγ), CXCL10 or IP10 (IFNγ-inducible 10 kDa protein), and CXCL11 or I-TAC (IFN-inducible T cell α-chemoattractant). CXCR3 plays an important role in regulating leukocyte trafficking; indeed binding of chemokines induces cellular responses that are involved in leukocyte traffic, most notably integrin activation, cytoskeletal changes, and chemotactic migration. CXCR3 is expressed primarily on activated T lymphocytes and NK cells and some epithelial cells and endothelial cells. It had been implicated that CXCR3 is highly expressed on pro-inflammatory human CD4+Th17 cells \[[@CR35]\], "pathogenic" human Th1/17 cells \[[@CR36]\], and myelin oligodendrocyte glycoprotein-specific CD4+ T cells in experimental autoimmune encephalomyelitis mice in combination with other biomarkers \[[@CR37]\]. Increased CXCR3 in portal tracts has also been reported in PBC patients \[[@CR27]\]. Additionally, levels of CXCR3 ligands are markedly increased in inflammatory liver diseases \[[@CR38], [@CR39]\], including PBC \[[@CR27]\]. Further, knockout of CXCR3 delays PBC progression in an animal model \[[@CR40]\]. Most importantly, our data indicates that CXCR3 expression in CD4+ T cells inversely correlates with methylation levels and positively correlates with duration of disease. The accumulated data suggest a critical role of the CXCR3/chemokine system in the development of autoimmune disorders. In addition to its role in lymphocyte recruitment to tissues, CXCR3 is also implicated in the development of Th1 cells within lymph nodes \[[@CR41]\]; thus, hypomethylation of CXCR3 and the consequent increased expression on CD4 T cells could promote disease progression through enhanced Th1 differentiation and increased recruitment. X chromosome demethylation has been shown to result in increased CXCR3 expression in lupus, suggesting this could be a common mechanism that contributes to the female susceptibility to autoimmune diseases \[[@CR4]\]. Our findings are in agreement with previous studies; nevertheless, our findings strongly suggest an epigenetic mechanism underlying the elevated CXCR3 expression in PBC.

There are significant limitations in our study that should be discussed. First, of the genes studied herein, we note there were no significant differences identified for UBE2A gene expression, although UBE2A has been demonstrated to be hypermethylated in CD4+ T cells. This suggests that UBE2A expression is regulated by other epigenetic mechanisms rather than by methylation. Second, the pathogenetic mechanisms that underlie CXCR3 demethylation remain to be defined. Third, our study did not include men with PBC. This is of particular interest given the relevant function of the X chromosome. Fourth, the CD4 bias is interesting and it will be important to determine if this bias is found on other T cell subpopulations, particularly Th17, Tregs, or Th1 cells, all of which require CXCR3 to enter the liver. Finally, further studies will also need to focus on the differential expression of central versus effector memory cells. Our data highlight, however, the critical importance of epigenetics in PBC and likely for other autoimmune diseases.

Conclusions {#Sec7}
===========

CXCR3 promoter demethylation in CD4+ T cells from PBC patients, supported by a significantly higher expression of CXCR3 in the same cell subtype, emphasizes the well-known role of CXCR3 in the pathogenesis of PBC. Moreover, CXCR3 expression levels in CD4+ T cells are significantly associated with duration of disease. Whether CXCR3 may contribute to the female susceptibility to PBC warrants further investigation.

Methods {#Sec8}
=======

Subjects {#Sec9}
--------

Fresh heparinized peripheral blood samples were obtained from 30 patients diagnosed with PBC and 30 unaffected age- and sex-matched controls \[[@CR11]\]. All patients (Table [2](#Tab2){ref-type="table"}) were female, and 90 % had readily detectable AMA; the diagnosis was made based on internationally accepted criteria \[[@CR11]\]. The mean age was 61 (43--78) years old (range years), and 100 % of them were taking ursodiol. Four percent of the PBC patients included in this study were histologically characterized as cirrhotics. Serum liver function tests were performed utilizing routine laboratory methods. Subjects were excluded from the study if they had malignancies or were using immunosuppressive drugs. Patients and controls were matched for age and sex. After approval from appropriate institutional review board, all subjects provided written informed consent prior to enrollment in the study. The study design is illustrated in Fig. [1](#Fig1){ref-type="fig"}.Table 2Clinical, biochemical, and serological characteristics of PBC patientsPBC patientsHealthy controls(*n =* 30)(*n =* 30)Mean age (years, range)64 (44--87)60 (42--79)Females (*n*, %)30 (100 %)30 (100 %)AMA positivity (*n*, %)28 (93 %)n.a.Liver cirrhosis (*n*, %)4 (13 %)n.a.Total bilirubin (mg/dl) (n.v. \<1.0)0.64 ± 0.390.73 ± 0.18Alkaline phosphatase (IU/l) (n.v. \<279)152.3 ± 207.3168 ± 24Alanine aminotransferase (U/l) (n.v. \<50)33 ± 2632 ± 9Albumin (g/dl) (n.v. \>3.5)4.33 ± 0.864.68 ± 0.03Length of follow-up (months, range)34 (14--56)n.a.Therapy with UDCA (*n*, %)28 (93 %)n.a.Liver biopsy (*n*, %)21 (72 %)n.a.Mean values ± standard deviation unless otherwise stated*n.a.* not applicable, *n.v.* normal value

CD14+, CD4+ T cell, and CD8+ T cell purification {#Sec10}
------------------------------------------------

Peripheral blood mononuclear cells (PBMC) were isolated by centrifugation on a Ficoll-Hypaque gradient for 30 min at 500*g*. First, CD14+ cells were isolated from PBMC by positive selection under endotoxin-free conditions using anti-CD14 conjugated microbeads (Miltenyi Biotec, San Diego, CA, USA). Thence, CD8+ cells were isolated from the eluate by positive selection using anti-CD8 conjugated microbeads (Miltenyi Biotec, San Diego, CA, USA). Finally, the CD4+ T cells were isolated by negative selection using a cocktail of antibodies against CD8, CD14, CD16, CD19, CD36, CD56, CD123, TCR γ/δ, and CD235a (Miltenyi Biotec, San Diego, CA, USA). Aliquots of the CD14+, CD8+, and CD4+ T cells were subjected to viability assays and flow cytometry analysis. The purity of these lymphocytic populations was \>95 % and the viability \>95 %. Genomic DNA from the isolated CD14+, CD8+, and CD4+ T cells was isolated using TRI Reagent (Sigma-Aldrich, St. Louis, MO, USA) \[[@CR42]\].

Methylated DNA immunoprecipitation and methylation microarrays {#Sec11}
--------------------------------------------------------------

DNA samples from PBC patients (*n* = 10) and controls (*n* = 10) were sonicated to generate fragments between 200 and 1000 base pairs (bp), and then immunoprecipitated with a murine monoclonal antibody that specifically recognizes 5-methylcytidine (Diagenode, Liège, Belgium). The immunoprecipitated DNA fragments were recovered using anti-mouse IgG magnetic beads. The MeDIP-enriched DNA was amplified by PCR using universal primers and a limited number of cycles (GenomePlex® Complete Whole Genome Amplification kit). The amplified DNA samples were then purified with QIAquick PCR purification kit (Qiagen, Valencia, CA, USA). One microgram of immunoprecipitated and reference DNA was tagged respectively with Cyanine-5 (Cy5) and Cyanine-3 (Cy3) labeled random 9-mers and then hybridized by the NimbleGen Array Hybridization Kit (Roche NimbleGen, Madison, WI, USA). The labeled DNA was then purified by isopropanol/ethanol precipitation. For array hybridization, Roche NimbleGen's Human Promoter plus CpG Island array was used, a 3 × 720k format array design containing 27,728 CpG islands and all well-characterized promoter regions (from about −2440 to +610 bp of the TSSs) totally covered by \~720,000 probes.

Bisulfite sequencing {#Sec12}
--------------------

The CpG island DNA methylation status was determined by sequencing bisulfite-modified genomic DNA \[[@CR43]\] from PBC patients (*n* = 20) and controls (*n* = 20). One microgram of genomic DNA was bisulfite-converted using the EpiTect Bisulfite Kit (Qiagen, Valencia, CA, USA). For each gene, primers were designed using the Methyl Primer Express v1.0 program (Life Technologies-Applied Biosystems, Carlsbad, CA, USA) corresponding to the region containing the oligonucleotide probe represented in the DNA methylation bead array. Ten positive recombinant clones were selected randomly and sequenced using ABI 3730 (Life Technologies-Applied Biosystems, Carlsbad, CA, USA). The methylation level of gene is assessed according to the percentage of the methylated CG sites in 10 clones. All primer sequences are listed in Additional file [1](#MOESM1){ref-type="media"}: Table S1.

Reverse transcription and quantitative polymerase chain reaction {#Sec13}
----------------------------------------------------------------

Total RNA was extracted from all isolated samples (PBC *n* = 30, controls *n* = 30) using TRI Reagent (Sigma-Aldrich, St. Louis, MO, USA). cDNA was synthesized from all different cell types using High Capacity cDNA Reverse Transcription Kits (Life Technologies-Applied Biosystems, Carlsbad, CA, USA). One hundred nanograms of cDNA in a total volume of 20 μl was amplified for 40 cycles on an Applied Biosystems 7900 HT Sequence Detection System, using a TaqMan Gene Expression Assay specific for CXCR3, UBE2A, FUNDC2, and IL1RAPL2 (Cat. \#4331182, \#4351372, Life Technologies-Applied Biosystems, Carlsbad, CA, USA). TaqMan® Gene Expression Assays consist of a pair of unlabeled PCR primers and a TaqMan® probe with a FAM™ dye label on the 5′ end and minor groove binder (MGB) nonfluorescent quencher (NFQ) on the 3′ end. RNA from samples of interest is reverse transcribed into cDNA, and the synthesized cDNA serves as the template for real-time PCR. ROX™ dye is used as a passive reference to normalize real-time PCR reactions. ROX™ dye provides an internal reference to which the FAM™ reporter dye signal can be normalized, which is necessary to correct for fluorescent fluctuations due to changes in concentration, volume, or light source intensity. Normalization of the reporter dye signal results in increased data precision. All reactions were run in duplicate. The relative mRNA expression level of each gene was determined by normalizing its mRNA level to the internal control glyceraldehyde 3-phosphate dehydrogenase (GAPDH).

Flow cytometry {#Sec14}
--------------

Phenotypic analysis of CD4 T cells was assessed using fluorochrome-conjugated monoclonal antibodies against cell surface markers on a FACSCantoII (BD Biosciences, San Diego, CA, USA) using FACSDiva™ software (BD Biosciences, San Diego, CA, USA). Monoclonal antibodies against human CD3, CD4, CD45RA, CD45RO, and CD183 (CXCR3) were purchased from BioLegend (San Diego, CA, USA). Frozen cells were thawed and prepared for flow cytometry as described \[[@CR44]\]. Cells were stained for 15 min at room temperature with Aqua viability dye (Life Technologies). Optimal concentrations of the mAbs were used throughout, and all assays included positive and negative controls.

Statistical methods {#Sec15}
-------------------

NimbleScan software v2.5 (Roche NimbleGen, Madison, WI, USA) was utilized for DNA methylation data analysis using a threshold *p* value of 0.05 equivalent to 1.31 based on the Gaussian distribution of data. Second, exclusive elements corresponding to specific microarray probes were identified using a one-sided Kolmogorov-Smirnov (KS) test in affected and healthy subjects; peaks found only in either group were selected for further analysis. Peaks within 500 bp of each other are merged. If several adjacent probes rise significantly above a set threshold, the region is assigned to an enrichment peak (EP). NimbleScan detects peaks by searching for at least two probes above a *p* value minimum cutoff (−log10) of 2. Third, elements of interest were inserted into the UCSC Genome Browser to identify corresponding genes. The filter condition of different methylated regions was set to be no less than six EPs in one group and not more than three EPs in the other group. Based on GO analysis and potential involvement in the pathogenesis of PBC, four genes were selected for validation using isolated CD4+, CD8+, and CD14+ cells from 20 additional patients with PBC and 20 additional normal controls. For RT-qPCR, the data were analyzed with Delta Delta Ct using global normalization. Statistical differences between groups were identified using an unpaired *t* test taking into account transcripts with *p* value \<0.05.

Additional file {#Sec16}
===============

Additional file 1:**Supplementary table.**

AMAs

:   antimitochondrial antibodies

GAPDH

:   glyceraldehyde 3-phosphate dehydrogenase

GWAS

:   genome-wide association

IP10

:   IFNγ-inducible 10 kDa protein

KS

:   Kolmogorov-Smirnov

MeDIP

:   methylated DNA immunoprecipitation

PBC

:   primary biliary cirrhosis

RT-qPCR

:   reverse transcription and quantitative polymerase chain reaction
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